Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $54437.0.

  • China Pharma Holdings' Change in Account Payables fell 7766.63% to $54437.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $202297.0, marking a year-over-year increase of 14301.99%. This contributed to the annual value of -$733916.0 for FY2024, which is 33519.56% down from last year.
  • According to the latest figures from Q3 2025, China Pharma Holdings' Change in Account Payables is $54437.0, which was down 7766.63% from -$19322.0 recorded in Q2 2025.
  • China Pharma Holdings' 5-year Change in Account Payables high stood at $442807.0 for Q3 2023, and its period low was -$505339.0 during Q2 2024.
  • In the last 5 years, China Pharma Holdings' Change in Account Payables had a median value of -$3413.0 in 2022 and averaged -$30754.4.
  • As far as peak fluctuations go, China Pharma Holdings' Change in Account Payables soared by 304576.62% in 2023, and later plummeted by 41487.08% in 2024.
  • Quarter analysis of 5 years shows China Pharma Holdings' Change in Account Payables stood at $311018.0 in 2021, then dropped by 23.32% to $238485.0 in 2022, then crashed by 54.75% to $107922.0 in 2023, then tumbled by 244.32% to -$155753.0 in 2024, then soared by 134.95% to $54437.0 in 2025.
  • Its last three reported values are $54437.0 in Q3 2025, -$19322.0 for Q2 2025, and $322935.0 during Q1 2025.